Source comparison
PT-141 Sexual Dysfunction Treatment Options Comparison
PT-141 (bremelanotide) Melanocortin MC3/MC4 receptor agonist. Acts centrally in hypothalamus to modulate arousal pathways 45–90 min for initial effect; full therapeutic benefit at 4–6 doses over 2–3 weeks Plasma half-life 2.7 hours; subjective arousal effect p
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- Melanocortin MC3/MC4 receptor agonist. Acts centrally in hypothalamus to modulate arousal pathways
- 45–90 min for initial effect; full therapeutic benefit at 4–6 doses over 2–3 weeks
- Plasma half-life 2.7 hours; subjective arousal effect persists 6–8 hours per dose
- 25–40% of patients report meaningful improvement in desire and arousal by week 4 (vs 17% placebo)
- Best for central desire disorders where the issue is motivation/arousal initiation, not physical dysfunction. Requires patience through titration period
- Sildenafil (Viagra)
- PDE5 inhibitor. Increases cGMP in genital tissue to enhance vasodilation and blood flow
- 30–60 min
- 4–6 hours
- 70–85% of men with ED achieve erections sufficient for intercourse
- Gold standard for erectile dysfunction caused by vascular insufficiency. Does not address desire or central arousal
- Tadalafil (Cialis)
- PDE5 inhibitor. Same mechanism as sildenafil but longer half-life
- 24–36 hours
- 70–80% efficacy for ED
- Preferred for men who want spontaneity without timing doses. Still peripheral mechanism only
- Flibanserin (Addyi)
- 5-HT1A agonist / 5-HT2A antagonist. Modulates serotonin and dopamine in prefrontal cortex
- Daily dosing for 4–8 weeks before effect appears
- Continuous (daily medication, not on-demand)
- 10–15% report meaningful improvement over placebo
- Modest efficacy, requires daily adherence, significant side effect profile (hypotension, sedation). PT-141 typically better tolerated
- Testosterone replacement
- Androgen receptor activation. Increases libido, energy, and baseline arousal threshold
- 2–4 weeks for subjective libido improvement; 8–12 weeks for full effect
- Continuous (requires ongoing therapy)
- 60–70% of hypogonadal men report improved desire
- Effective only when low testosterone is the root cause. Does not address CNS arousal pathways in eugonadal patients